孤立性骨浆细胞瘤伴或不伴骨髓受累的多中心进展风险与结局研究
该多中心研究比较了141例孤立性骨浆细胞瘤(SBP)和102例伴轻微骨髓受累的SBP(SBPmm)接受根治性放疗后的结局。del(17p)和1q+与SBPmm更短TTP相关。
要点
- SBPmm进展为MM的风险显著高于SBP(92% vs 76%),且中位TTP更短(15 vs 43个月)。
- SBPmm患者67%在诊断后2年内进展,del(17p)和1q+者2年进展率分别达100%和82%。
- 多数进展以多发性溶骨性骨病变为骨髓瘤定义事件(SBPmm 89%,SBP 81%)。
核心结论
- SBPmm较SBP进展为MM的风险更高、时间更早,多数以骨病变为骨髓瘤定义事件。
- 研究支持对SBPmm开展含一线全身治疗的前瞻性研究。
主要发现
- SBPmm患者67%在诊断后2年内进展。
- 多发性溶骨性骨病变是最常见MDE,SBPmm和SBP分别占89%和81%。
关键数值与推荐
- del(17p)和1q+(获得或扩增)与SBPmm更短TTP相关,2年进展率分别为100%和82%。
- 初始放疗后TTP较长的患者,在无其他MDE时可对第二处孤立浆细胞瘤行放疗获得持久缓解。
临床怎么用
- SBPmm患者进展风险高且多在2年内发生,应密切监测。
- del(17p)或1q+的SBPmm患者可能需更积极干预,支持前瞻性研究一线全身治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Solitary bone plasmacytoma (SBP) and SBP with minimal marrow involvement (SBPmm) are treated similarly with definitive radiation therapy (RT) followed by observation. However, differences in the natural disease course after RT between the two, are not well described. We performed a multicenter study assessing outcomes after RT in 141 patients with SBP and 102 with SBPmm diagnosed between January 2010 and December 2024. About 92% of patients with SBPmm progressed to multiple myeloma (MM) vs 76% of those with SBP (P = .01). Among patients with SBP, 21% progressed with a second solitary bone lesion vs 4% with SBPmm (P< .01). Patients with longer time to progression (TTP) after initial RT could achieve durable responses with RT to a second solitary plasmacytoma in the absence of other myeloma-defining events (MDE). Multifocal lytic bone lesions were the most common MDE, occurring in 89% and 81% of patients with SBPmm and SBP, respectively. Patients with SBPmm had a median TTP of 15 months (95% confidence interval [CI], 14-21) compared to 43 months (95% CI, 34-55) for those with SBP (P< .0001); 67% with SBPmm progressed within 2 years of diagnosis. Del(17p) and 1q+ (gain or amplification) were associated with shorter TTP to MM in SBPmm, with 2-year progression rates of 100% and 82%, respectively. We report significant differences in risk and modes of progression between SBP and SBPmm. Patients with SBPmm are at particularly high risk for early progression to MM, with most developing bone disease as the MDE. These findings support prospective studies incorporating frontline systemic therapy for SBPmm.
引用
- Lim KJC, Steinhardt M, Rees MJ, et al. A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement. Blood Adv. 2026. PMID: 42018661. doi:10.1182/bloodadvances.2025019136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。